140 A prospective trial on the efficacy and tolerability of twice-daily dosing (TDD) versus once-daily dosing (ODD) amikacin in cystic fibrosis patients

Постников, С. С.; Semykin, S. Yu.; Поликарпова, С. В.; Dubovik, L.G.; Gracheva, L. A.; Sagatelyan, R.M.

doi:10.1016/s1569-1993(07)60126-x

Cited by 16 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, it is a small, cross-over trial for which separate first-arm data have not yet been provided. We have contacted the author again (18 April 2018) for additional information and we will include this in a future update, if these data become available.Two further trials are currently awaiting classification (Postnikov 2007;Semykin 2010) and one new trial is listed in Ongoing studies. A flow chart showing the process of trial selection is presented in the figures (Figure 1).…”

Section: Results Of the Searchmentioning

confidence: 99%

“…One trial is a two-arm cross-over trial which lasted two weeks and recruited 15 children aged between seven and 17 years of age (Postnikov 2007). Participants received either once-daily or twice-daily amikacin at a dose of between 15 mg/kg/day and 20 mg/kg/day in combination with ce azidime or meropenem.…”

Section: Studies Awaiting Classificationmentioning

confidence: 99%

“…The investigators planned to report on lung function, microbiology and adverse events at baseline and at day 14. It is currently not clear from the abstract whether the amikacin was inhaled or IV (Postnikov 2007).…”

Section: Studies Awaiting Classificationmentioning

confidence: 99%

See 2 more Smart Citations

Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis

Smith

Rowbotham

Charbek³

2018

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background Cystic fibrosis is a genetic disorder in which abnormal mucus in the lungs is associated with susceptibility to persistent infection. Pulmonary exacerbations are when symptoms of infection become more severe. Antibiotics are an essential part of treatment for exacerbations and inhaled antibiotics may be used alone or in conjunction with oral antibiotics for milder exacerbations or with intravenous antibiotics for more severe infections. Inhaled antibiotics do not cause the same adverse e ects as intravenous antibiotics and may prove an alternative in people with poor access to their veins. This is an update of a previously published review. Objectives To determine if treatment of pulmonary exacerbations with inhaled antibiotics in people with cystic fibrosis improves their quality of life, reduces time o school or work and improves their long-term survival. Search methods We searched the Cochrane Cystic Fibrosis Group's Cystic Fibrosis Trials Register.

show abstract

Section: Results Of the Searchmentioning

confidence: 99%

Section: Studies Awaiting Classificationmentioning

confidence: 99%